In this phase 2 double-blind trial, adults with treatment-resistant depression were randomly assigned to receive psychological support and a single dose of a proprietary, synthetic form of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control). The Montgomery-Sberg Depression Rating Scale (MADRS) total score change from baseline to week three was the main outcome measure. Secondary endpoints included remission at week 3, response at week 3, and sustained response at 12 weeks.

This article provides a brief review of three important books on the thinking and experience around psychedelics in medicine: The Promise of Psychedelics, by Peter Silverstone, MD; Psychedelic Medicine, by Richard Louis Miller, MA, PhD; How to Change Your Mind, by Michael Pollan.

This overview and discussion highlights the learnings gleaned during practice in a ketamine service unit. Discussion points include treatment considerations for the two entities, switching from IV to intranasal, and a collection of pearls.

Basimglurant is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5). Based on the LibraTN trial — a 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study of basimglurant for trigeminal neuralgia, FDA has granted the molecule Fast Track designation.

Sleep disorders are common in persons with psychiatric disease. In most cases the disorder is related to mutations in the circadian clock regulatory gene or decreased endogenous melatonin secretion, whether primary or secondary. Melatonin administration is usually beneficial.

In an article originally published in JAMA Neurology, the authors state that long-term clinical and cinematic follow-up point to young-onset tremor-dominant idiopathic Parkinson’s disease rather than boxing injury.